Chad Robins co-founded Adaptive Biotechnologies in September 2009 and has served as its Chief Executive Officer and a member of the board of directors since incorporation, and as Chairman of the board. Under his leadership Adaptive built its immune medicine platform spanning life sciences research, clinical diagnostics and drug discovery, completed its 2019 IPO and launched clonoSEQ, the first FDA-authorized next-generation-sequencing test to detect and monitor minimal residual disease in certain B-cell cancers. He currently serves on the boards of Headlight, Washington Roundtable, AltPep, AdvaMedDx and Life Science Washington, and chairs the board of the Coalition for 21st Century Medicine. He is the brother of Chief Scientific Officer Harlan Robins. Mr. Robins holds an MBA from The Wharton School at the University of Pennsylvania and a BS in Managerial Economics from Cornell University.